Coridon HSV-2 vaccine shows 100% efficacy

Brisbane, Australia-based biotech Coridon has developed a DNA vaccine for herpes simplex virus 2 that showed 100% efficacy in a preclinical trial. Thanks to financial backing from Allied Healthcare Group, Coridon hopes to push the vaccine into human trials in the next year. As a DNA vaccine, the HSV-2 vax can be used both for preventative and curative measures. Article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.